The Definitional Boundaries of Medical Equipment under UAE Law: Reading Articles 1 and 2

1. Key takeaways

Whether the same product is recognised as a medical device directly determines whether it needs a marketing authorization, and it equally determines how much compliance resource the company must invest. Our reading is that Article 1 provides the definitional elements and Article 2 provides the boundary of scope, and the two must be read together — Article 1 answers what the product is, and Article 2 answers which products are brought in. For products with blurred boundaries, the official channel is the EDE classification service, with an official timeline of 10 working days, which issues a classification letter confirming the regulatory category and whether a marketing authorization is required. We recommend using a four-step method to make an internal pre-assessment first, and then deciding whether to submit a classification application.

• Article 1 supplies the definitional elements; Article 2 supplies the boundary of scope; the two provisions must be read together.
• The official channel for boundary questions is the EDE classification service, with an official timeline of 10 working days.
• The classification letter confirms the regulatory category and whether a marketing authorization is required.
• An internal four-step pre-assessment should precede any decision to submit a classification application.

2. Legal basis

The table below lists the defining provisions of the decree and the documents that the EDE classification service requires, which together form the textual foundation for every boundary judgement described in this article.

3. Expert insights

Insight 1: The contested point of the definitional boundary lies in the intended use, not in the technical construction. Our judgement is that the overwhelming majority of review-stage disagreements over whether a product is a medical device originate in the intended use and claims written by the manufacturer itself. The same hardware, claimed for the diagnosis of human disease and claimed for industrial testing, will produce entirely different conclusions. The first step of a boundary judgement should therefore be to lock down the manufacturer’s external claims, rather than to compare technical parameters. This is also why we require companies to unify the wording across the official website, the instructions for use and the promotional materials before submitting a classification application.

Insight 2: The third step of the four-step method must land on written evidence, and cannot remain at the level of internal discussion. The four-step method we use is: lock down the intended use and claims, then compare item by item against the definitional elements of Article 1, then confirm the category attribution against the scope of Article 2, and finally fix the conclusion with an EDE classification letter or a written enquiry. The reasoning is that Article 6(1)(g) requires the information on the inner and outer packaging and the instructions for use to be complete and consistent with the EDE labelling guidance; once the internal conclusion and the external documents diverge, the inconsistency will be picked up directly at the technical review stage.

Insight 3: The timing of the classification-letter application should precede dossier preparation, not follow a deficiency notice. We maintain that classification should be confirmed before the product enters dossier preparation. The reason is that the classification conclusion determines the hierarchy of evidence: different categories correspond to different quality-conformity documents and different requirements for safety and effectiveness data. Classifying first and preparing afterwards avoids the rework caused by organising evidence at the wrong tier. Among the documents required by the classification service is a certificate of product status from the competent authority of the country of origin (CPP/CFS/ISO/CE), and the acquisition lead time for such documents should be built into the schedule (practical estimate: from zero preparation to formal market entry, 6–18 months).

4. Practical recommendations

• Establish a unified wording for the intended use and claims, covering the registration dossier, the instructions for use, the official website and promotional materials, so that conflicting statements do not appear across documents.
• For products with blurred boundaries, prioritise submitting an EDE classification application — the official timeline is 10 working days — replacing internal inference with a written conclusion.
• Prepare the classification application documents in one pass according to the service-page checklist: product catalogue, product images, certificates from the country of origin, instructions for use and label artwork for the inner and outer packaging.
• Once the classification conclusion is issued, use it as the single basis for organising the technical documentation, designing the labelling and setting the vigilance tier.
• When the intended use, the target patient population or the environment of use changes, re-evaluate the classification conclusion rather than carrying forward the historical judgement.
• For product families with multiple specifications and models, decide whether to combine the classification applications according to whether the intended use is substantially the same, avoiding repeated applications model by model.

5. Verification checklist

• □ The unified wording check of intended use and external claims has been completed, with no conflicting statements across documents.
• □ An item-by-item comparison against the definitional elements of Article 1 has been completed and a written conclusion formed.
• □ The product’s category attribution has been confirmed under Article 2, including the applicability judgement for free-zone scenarios.
• □ An EDE classification letter has been obtained, or a classification application has been submitted and an acceptance number received.
• □ The classification application documents have been confirmed complete, with the certificates from the country of origin within their validity.
• □ The classification conclusion has been confirmed to match the tier of quality-conformity documents and safety and effectiveness data to be submitted.
• □ Trigger conditions and a re-evaluation process for changes to the classification conclusion have been established.

Further reading: Article 02 “Scope of Federal Decree-Law No. 38/2024: Which Category of Medical Products Covers Medical Devices”; Article 04 “The Three-Tier Regulatory Structure for Medical Devices in the UAE: EDE, MOHAP and the Emirate-Level Health Authorities”; Article 11 “Classification First: The EDE Classification Letter (10 Working Days) and the Class I–IV Risk Grading”.

Regulatory information verified as of October 29, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the United Arab Emirates. Our team manages MOHAP registrations and free-zone (DHCC) pathways, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com